Want to see NPCE full AI Analyst Report?
NPCE Stock Chart & Stats
$14.81
$0.13(0.89%)
At close: 4:00 PM EDT
$14.81
$0.13(0.89%)
Day’s Range― - ―
52-Week Range$7.56 - $19.60
Previous CloseN/A
Volume268.93K
Average Volume (3M)181.28K
Market Cap
$468.79M
Enterprise Value$459.86
Total Cash (Recent Filing)$53.98M
Total Debt (Recent Filing)$70.46M
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Aug 06, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding34,093,746
10 Day Avg. Volume169,331
30 Day Avg. Volume181,278
Financial Highlights & Ratios
PEG Ratio0.81
Price to Book (P/B)26.55
Price to Sales (P/S)5.05
P/FCF Ratio-44.56
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$20.33Price Target Upside37.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.65
Revenue Forecast (FY)$99.91M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained gross margins above 80% reflect strong device economics and pricing power for the RNS System. High product margins create durable operating leverage as sales scale, helping the company convert incremental revenue into improved cash generation and insulating core profitability from volume variability.
Robust Long-term Clinical OutcomesConsistent, prospectively collected long-term outcomes provide durable clinical differentiation versus alternatives. Strong efficacy data supports physician adoption, referral growth, payer coverage discussions, and sustained implant volume over multi-year horizons, strengthening the commercial runway beyond short-term cycles.
Proprietary AI Roadmap And DatasetA unique, large intracranial data asset and active AI development create a structural moat. AI-enabled diagnostics and clinician tools can improve therapy outcomes and workflow, support higher clinical stickiness, enable service revenue, and raise barriers to entry for competitors over the next several years.
Bears Say
Elevated Leverage And Thin Equity CushionHigh leverage relative to a shrunken equity base reduces financial flexibility and increases insolvency and dilution risk if cash burn reaccelerates. Elevated debt loads constrain ability to fund growth or respond to regulatory delays without costly external financing or shareholder dilution.
Negative Operating And Free Cash FlowPersistent negative cash flow, even if improved versus prior years, implies ongoing reliance on financing to fund operations and commercialization. Continued FCF deficits over multiple quarters would pressure liquidity, limit reinvestment capacity, and increase the probability of capital raises that dilute shareholders.
Regulatory Setback Delaying Label ExpansionA non-approvable determination delays entry into the IGE patient population and defers diversification of revenue streams. Prolonged regulatory work raises timing and reimbursement uncertainty, constraining near- to medium-term addressable market expansion and heightening execution risk tied to a single core indication.
NeuroPace News
NPCE FAQ
What was Neuropace, Inc.’s price range in the past 12 months?
Neuropace, Inc. lowest stock price was $7.56 and its highest was $19.60 in the past 12 months.
What is Neuropace, Inc.’s market cap?
Neuropace, Inc.’s market cap is $468.79M.
When is Neuropace, Inc.’s upcoming earnings report date?
Neuropace, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 4 days.
How were Neuropace, Inc.’s earnings last quarter?
Neuropace, Inc. released its earnings results on May 12, 2026. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.23 by $0.03.
Is Neuropace, Inc. overvalued?
According to Wall Street analysts Neuropace, Inc.’s price is currently Undervalued.
Does Neuropace, Inc. pay dividends?
Neuropace, Inc. does not currently pay dividends.
What is Neuropace, Inc.’s EPS estimate?
Neuropace, Inc.’s EPS estimate is -0.22.
How many shares outstanding does Neuropace, Inc. have?
Neuropace, Inc. has 34,093,746 shares outstanding.
What happened to Neuropace, Inc.’s price movement after its last earnings report?
Neuropace, Inc. reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.23. Following the earnings report the stock price went up 0.063%.
Which hedge fund is a major shareholder of Neuropace, Inc.?
Currently, no hedge funds are holding shares in NPCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeuroPace Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.33 (37.29% Upside)
$20.33 (37.29% Upside)
Blogger Sentiment
Bullish
NPCE Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 59.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 4.0%
Last 30 Days ▼ 25.9%
Last 30 Days ▼ 25.9%
News Sentiment
Bullish
Bullish news 80%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.37%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-10.26%
Trailing 12-Months
Company Description
Neuropace, Inc.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
NPCE Company Deck
NPCE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial and clinical momentum: double-digit RNS revenue growth (CFO reported ~20% YoY excluding DIXI), raised full-year guidance, improved adjusted EBITDA outlook, robust clinical data (NAUTILUS 18-month and 3-year focal outcomes), and tangible AI/product roadmap progress. Offsetting risks include the NAUTILUS primary endpoint nuance, IGE revenue timing and payer coverage uncertainty, seasonally lower cash, and ongoing need for reimbursement work. Overall, management presented disciplined investment and operating leverage alongside meaningful opportunities that outweigh near-term risks.View all NPCE earnings summariesNPCE Stock 12 Month Forecast
Average Price Target
$20.33
▲(37.29% Upside)
Technical Analysis
Delcath Systems
―
Senseonics Holdings
―
Tactile Systems Technology
―
RxSight
―
Ceribell, Inc.
―
Ownership Overview
16.75% Insiders
9.75% Mutual Funds
42.19% Other Institutional Investors
15.03% Public Companies and
Individual Investors